23511-04-8

Basic information

• Product Name: 4-Oxocyclohexan-1-ol p-toluenesulfonate
• Synonyms: 4-Oxocyclohexan-1-ol p-toluenesulfonate
• CAS NO: 23511-04-8
• Molecular Formula: C₁₃H₁₆O₄S
• Molecular Weight: 268.33
• Mol File: 23511-04-8.mol
• Article Data: 9

Chemical Properties

• Melting Point: 94-95 °C(Solv: carbon disulfide (75-15-0))
• Boiling Point: 431.2°C at 760 mmHg
• Flash Point: 214.6°C
• Appearance: /
• Density: 1.28g/cm³
• Vapor Pressure: 1.22E-07mmHg at 25°C
• Refractive Index: 1.56
• CAS DataBase Reference: 4-Oxocyclohexan-1-ol p-toluenesulfonate(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Oxocyclohexan-1-ol p-toluenesulfonate(23511-04-8)
• EPA Substance Registry System: 4-Oxocyclohexan-1-ol p-toluenesulfonate(23511-04-8)

Safety Data

• Hazardous Substances Data: 23511-04-8(Hazardous Substances Data)

Usage

InChI:InChI=1/C13H16O4S/c1-10-2-8-13(9-3-10)18(15,16)17-12-6-4-11(14)5-7-12/h2-3,8-9,12H,4-7H2,1H3

Upstream product

• 111859-02-0 cis-4-methoxycyclohexyl tosylate 
• 4746-97-8 cyclohexanedione monoethylene ketal 
• 13482-22-9 4-hydroxycyclohexanone 
• 98-59-9 p-toluenesulfonyl chloride 
• 23511-05-9 toluene-4-sulfonic acid 1,4-dioxa-spiro[4.5]dec-8-yl ester 
• 111859-02-0 cis-1-methoxy-4-tosyloxycyclohexane 
• 556-48-9 1,4-Cyclohexanediol 
• 92121-36-3 4-hydroxycyclohexyl 4-methylbenzene-1-sulfonate 

Downstream Products

• 99249-37-3 3-cyclohexen-1-one cyclic (1S,2S)-1,2-bis-<(benzyloxy)methyl>ethylene acetal 
• 1067230-56-1 toluene-4-sulfonic acid 4,4-difluorocyclohexyl ester 
• 822-58-2 cis-2-bicyclo[3.1.0]hexanol 
• 855609-85-7 1-hydroxy-4-(toluene-4-sulfonyloxy)-cyclohexanecarboxylic acid amide 
• 22460-52-2 4-bromocyclohexan-1-one 
• 31053-10-8 4-iodocyclohexan-1-one 

Relevant articles and documents

(8β)-Ergoline-8-carboxylic acid cycloalkyl esters as serotonin antagonists: Structure-activity study

A series of (8β)-6-methyl-1-(1-methylethyl)ergoline-8-carboxylic acid cycloalkyl esters were prepared and examined for blockade of vascular 5HT2 receptors. The antagonist in this series that had the highest 5HT2 receptor affinity was

COMPOUND SERVING AS IRAK INHIBITOR

The present disclosure relates a compound as an IRAK inhibitor. Specifically, the present disclosure provides a compound of formula I, or a cis-trans isomer, an optical isomer, a racemate, a pharmaceutically acceptable salt, a prodrug, a deuterated derivative thereof, a hydrate or a solvate thereof. The compounds disclosed herein have potent inhibitory effects on IRAK and thus have therapeutic effect on IRAK-related diseases.

FUSED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTCIAL COMPOSITION, AND USES THEREOF

Disclosed are a fused heterocyclic compound, a preparation method therefor, a pharmaceutical composition, and uses thereof. The fused heterocyclic compound is shown in formula I, formula II, or formula III. The preparation method of the fused heterocyclic compound and/or the pharmaceutically acceptable salt thereof in the present invention comprises three synthesizing routes. The present invention also provides a pharmaceutical composition of the fused heterocyclic compound, the pharmaceutical composition containing one or more of the fused heterocyclic compound shown in formula I, formula II, or formula III, the pharmaceutically acceptable salt thereof, hydrates, solvent compounds, polymorphs and prodrugs thereof, and a pharmaceutically acceptable carrier. The present invention also relates to an application of the fused heterocyclic compound and/or the pharmaceutical composition in preparing kinase inhibitors and in preparing drugs for preventing and treating diseases related to kinase. The fused heterocyclic compound of the present invention has selective inhibition function on PI3Kδ, and can be used for preparing drugs for preventing and treating cell proliferation diseases such as cancers, infections, inflammations, or autoimmune diseases.

Unified oxidation protocol for the synthesis of carbonyl compounds using a manganese catalyst

We have developed a unified protocol for the oxidation of ethers, benzylic compounds, and alcohols to carbonyl compounds. The protocol uses catalytic amounts of manganese(II) chloride tetrahydrate and tri(t-butyl)-2,2':6',2Prime;- terpyridine in combination with a stoichiometric amount of either m-chloroperbenzoic acid (MCPBA) or potassium hydrogen peroxysulfate (KHSO 5). A reagent system consisting of the Mn catalyst and MCPBA permitted the chemoselective sp3 C-H oxidation of alkyl ethers and benzylic compounds to generate the corresponding ketones. Alternatively, the water-soluble inorganic salt KHSO5 in combination with the Mn catalyst was used to oxidize alcohols to ketones or carboxylic acids. Importantly, the Mn catalyst/KHSO5 system eliminates technical difficulties associated with the isolation of carboxylic acid products. All the oxidations presented in this feature article proceed at sup-ambient temperature in an aerobic atmosphere, and can therefore be used in practical syntheses of complex organic molecules. Georg Thieme Verlag Stuttgart · New York.